[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339341-105":59,"doc-detail-339341-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","the-combination-of-breast-cancer-pdo-and-mini-pdx-platform-for-drug-screening-and-individualized-treatment","The combination of breast cancer PDO and mini-PDX platform for drug screening and individualized treatment","","Advanced breast cancer is characterized by aggressiveness, heterogeneity, and drug resistance, making effective tailored strategies urgently needed. A preclinical workflow was built using organoid biobanks from 17 patients, characterized by IHC and NGS, and combined patient-derived organoids with mini-PDXs for rapid drug-sensitivity screening. Breast cancer organoids were validated as high-fidelity 3D models reproducing histological and genetic features, enabling individualized agent combinations.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-combination-of-breast-cancer-pdo-and-mini-pdx-platform-for-drug-screening-and-individualized-treatment/339341/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-combination-of-breast-cancer-pdo-and-mini-pdx-platform-for-drug-screening-and-individualized-treatment/339341.png","ImageObject",300,407,{"name":92,"@type":93},"Aurora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does the study aim to address in advanced breast cancer?","Question",{"text":113,"@type":114},"It targets the lack of effective treatment strategies due to aggressiveness, heterogeneity, and drug resistance in advanced breast cancer.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were the patient-derived models established and characterized?",{"text":118,"@type":114},"Organoid biobanks were created from 17 patients and characterized using immunohistochemistry (IHC) and next generation sequencing (NGS).",{"name":120,"@type":111,"acceptedAnswer":121},"What is the purpose of combining PDOs with mini-PDXs?",{"text":122,"@type":114},"The combination is used for rapid and precise screening of drug sensitivity to identify potentially effective therapeutic agent combinations for individual patients.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},339341,1790153430,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","DOI: 10. 1111/jcmm.18374  \nOR I G I NAL ART I C L E  \nThe combination of breast cancer PDO and mini-PDX platform for drug screening and individualized treatment  \nYuxin Cui1,2,3 | Ran Ran1,2,3 | Yanyan Da1,4 | Huiwen Zhang1 | Meng Jiang1,2,3 | Xin Qi1,2,3 | Wei Zhang5 | Ligang Niu5 | Yuhui Zhou5 | Can Zhou5 | Xiaojiang Tang5 | Ke Wang5 | Yu Yan5 | Yu Ren5 | Danfeng Dong1,2,3 | Yan Zhou1,2,3 | Hui Wang1,2,3 | Jin Gong1,2,3 | Fang Hu1,2,3 | Shidi Zhao1,2,3 | Huimin Zhang5  |  \nChengsheng Zhang1,2,4 | Jin Yang1,2,3   \n1Precision Medicine Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China 2Cancer Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China  \n3 Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China  \n4Center for Molecular Diagnosis and Precision Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China 5Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China  \nCorrespondence  \nHuimin Zhang, Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China.  \nEmail: [huimin.zhang@xjtu.edu.cn](huimin.zhang@xjtu.edu.cn)  \nChengsheng Zhang and Jin Yang, Precision Medicine Center, The First Affiliated Hospital of Xi'an Jiaotong University,  \nXi'an, Shaanxi, People's Republic of China. Email: [cszhang99@126.com](cszhang99@126.com) and yangjin@ [xjtu.edu.cn](xjtu.edu.cn)  \nAbstract  \nThe majority of advanced breast cancers exhibit strong aggressiveness, heterogeneity, and drug resistance, and currently, the lack of effective treatment strategies is one of the main challenges that cancer research must face. Therefore, developing a feasible preclinical model to explore tailored treatments for refractory breast cancer is urgently needed. We established organoid biobanks from 17 patients with breast cancer and characterized them by immunohistochemistry (IHC) and next generation sequencing (NGS) . In addition, we in the first combination of patient-derived organoids (PDOs) with mini-patient-derived xenografts (Mini-PDXs) for the rapid and precise screening of drug sensitivity. We confirmed that breast cancer organoids area high-fidelity three-dimension (3D) model in vitro that recapitulates the original tumour's histological and genetic features. In addition, for a heavily pretreated patient with advanced drug-resistant breast cancer, we combined PDO and Mini-PDX models to identify potentially effective combinations of therapeutic agents for this patient who were alpelisib + fulvestrant. In the drug sensitivity experiment of organoids, we observed changes in the PI3K/AKT/mTOR signalling axis and oestrogen receptor (ER) protein expression levels, which further verified the reliability of the screening results. Our study demonstrates that the PDO combined with mini-PDX model offers a rapid and precise drug screening platform that holds promise for personalized medicine,  \n\n| Yuxin Cui, Ran Ran and Yanyan Da contributed equally to this work. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\u003Cbr>© 2024 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. |\n\nJ Cell Mol Med. 2024;28:e18374 .  \n[https://doi.org/10.1111/jcmm.18374](https://doi.org/10.1111/jcmm.18374)  \n[wileyonlinelibrary.com/journal/jcmm](wileyonlinelibrary.com/journal/jcmm)  \n1 of 14  \nimproving patient outcomes and addressing the urgent need for effective therapies in advanced breast cancer.  \n1 | INTRODUCTION  \nAccording to the latest ","cbCaigSP2ioPO6sR","https://ap.wps.com/l/cbCaigSP2ioPO6sR","pdf",31195544,14,"English","# Introduction\n## Clinical burden and drug resistance\n## Current preclinical models and limitations\n## Rationale for PDO and mini-PDX integration","[{\"question\":\"What problem does the study aim to address in advanced breast cancer?\",\"answer\":\"It targets the lack of effective treatment strategies due to aggressiveness, heterogeneity, and drug resistance in advanced breast cancer.\"},{\"question\":\"How were the patient-derived models established and characterized?\",\"answer\":\"Organoid biobanks were created from 17 patients and characterized using immunohistochemistry (IHC) and next generation sequencing (NGS).\"},{\"question\":\"What is the purpose of combining PDOs with mini-PDXs?\",\"answer\":\"The combination is used for rapid and precise screening of drug sensitivity to identify potentially effective therapeutic agent combinations for individual patients.\"}]","The combination of breast cancer PDO and mini-PDX platform for drug screening and individualized treatment | PDF",1790029716,35,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e0adc6ecdc9e46ba30334c1105dffec.webp",983,1291,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa3de59e675055e4b350b8f734b9460d.webp",982,1290,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/677e57c12ebc70a0419180e3adaa92d2.webp",981,1289,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4230c19755396caffc137a646bcc7a50.webp",980,1287]